1. Home
  2. Development

Tags : Development

Biogen Signs a License Agreement with ViGeneron for Ophthalmic Gene Therapy Development
Biotech

Biogen Signs a License Agreement with ViGeneron for Ophthalmic Gene

Tuba Khan January 5, 2021

Shots: ViGeneron to receive an up front and R&D funding for the mutually agreed workplan and will receive development, regulatory and commercial milestone payments along with royalties on sales of products arising from the collaborations ViGeneron will optimize and validate in vitro therapeutic candidates for undisclosed target to treat inherited eye disease while Biogen has […]Read More

Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis
Pharma

Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis

Tuba Khan December 31, 2020

Shots: The companies collaborated to evaluate ruxolitinib in combination with CK0804 in patients with MF and plan to initiate a P-Ib study. Incyte will fund the study while operationalized by Cellenkos Cellenkos to receive $20M as licensing fee, ~$294.5M as development, regulatory and commercialization milestones along with royalties on sales of therapies, if approved. Incyte […]Read More

Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greater China
Biosimilars

Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology

Tuba Khan December 29, 2020

Shots: Cullinan will receive $20M up front and is eligible to receive ~$211M in development, regulatory and sales-based milestone payments Cullinan is also eligible for high-single-digit to low-teen tiered royalties based on sales of CLN-081 in Greater China includes Hong Kong, Macau and Taiwan CLN-081 is an orally available, small-molecule, irreversible EGFR inhibitor, which is […]Read More

Chugai In-Licenses Roche’s Antibody Cocktail for COVID-19 in Japan
Biotech COVID-19

Chugai In-Licenses Roche’s Antibody Cocktail for COVID-19 in Japan

Tuba Khan December 11, 2020

Shots: Chugai get an exclusive development and commercialization agreement in Japan for Roche’s Ab cocktail of casirivimab and imdevimab to combat COVID-19 Earlier, Roche & Regeneron collaborated for the development & commercialization of Ab cocktail where Regeneron will distribute the treatment in the US while Roche will be lead manufacturing and distribution activities outside the […]Read More

Evotec Collaborates with Rappta Therapeutics to Focus on Oncology Target
Pharma

Evotec Collaborates with Rappta Therapeutics to Focus on Oncology Target

Tuba Khan November 25, 2020

Shots: Evotec to receive research funding & is eligible for milestones. Evotec will support Rappta’s program of developing small molecule activators of the enzyme PP2A The collaboration leverages Evotec’s integrated platform for drug discovery and development and its oncology expertise coupled with state-of-the-art technologies PP2A is a serine/threonine phosphatase that functions as a tumor suppressor […]Read More

Pfizer And LianBio Collaborate to Expand the Development of Novel Therapeutics in Greater China
Pharma

Pfizer And LianBio Collaborate to Expand the Development of Novel

Tuba Khan November 20, 2020

Shots: Pfizer & LianBio collaborate to focus at developing & commercializing transformative therapies in Greater China. Both the companies will leverage their clinical development, regulatory and commercial expertise Pfizer will contribute ~$70M of non-dilutive capital toward in-licensing & co-development. At LianBio’s discretion, products will be presented to Pfizer for joint development Pfizer will have a […]Read More

J&J and US Government Amends their Agreement for the Next Phase of COVID-19 Vaccine Development
Biotech

J&J and US Government Amends their Agreement for the Next

Tuba Khan November 16, 2020

Shots: J&J and the US Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development Janssen will commit ~$604M while BARDA will commit ~$454M to support the ongoing P-lll ENSEMBLE study assessing Janssen’s JNJ-78436735 as a single-dose in ~60,000 patients globally J&J affirmed […]Read More

SomaLogic Collaborates with the US FDA to Advance Biosimilar Development
Biosimilars

SomaLogic Collaborates with the US FDA to Advance Biosimilar Development

Tuba Khan October 29, 2020

Shots: SomaLogic collaborate with the FDA to identify circulating pharmacodynamic biomarkers and analytical approaches that could be used to demonstrate bio-similarity of biosimilar to a reference FDA-approved biologic drug The collaboration will utilize the SomaLogic proteomic technology for the identification of circulating pharmacodynamic biomarkers for therapeutic biologics SomaLogic’s SomaScan platform makes 5,000 protein measurements simultaneously […]Read More

Copyright ©2021 PharmaShots | Powered by Octavus Consulting